Literature DB >> 19020759

Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.

Hirotoshi Kobayashi1, Kenichi Sugihara, Hiroyuki Uetake, Tetsuro Higuchi, Masamichi Yasuno, Masayuki Enomoto, Satoru Iida, Mizutomo Azuma, Ryutaro Mori, Akiko Omori, Heinz-Josef Lenz, Kathleen D Danenberg, Peter V Danenberg.   

Abstract

5-fluorouracil (5-FU) and oxaliplatin play important roles in chemotherapy for patients with colorectal cancer. The expression levels of thymidylate synthase (TS) and excision repair cross-complementing factor 1 (ERCC1) have been reported to be prognostic markers for patients with 5-FU/oxaliplatin chemotherapy. The aim of this study was to clarify the association between messenger RNA (mRNA) levels of TS and ERCC1 in primary colorectal cancer and those in corresponding liver metastasis. Formalin-fixed paraffin-embedded tumor specimens of 31 patients with resection for both colorectal cancer and liver metastasis were dissected by laser capture microdissection. After RNA extraction, TS and ERCC1 mRNA levels in both primary tumor and corresponding liver metastasis were measured by real-time reverse transcription-polymerase chain reaction. Both TS and ERCC1 mRNA levels in primary tumors were significantly associated with those in synchronous liver metastases (TS, rs=0.875, p=0.0024; ERCC1, rs=0.835, p=0.0038). TS mRNA levels in primary tumors were also associated with those in metachronous liver metastases (rs=0.659, p=0.0065), but not in ERCC1 (rs=0.319, p=0.19). In both genes, mRNA levels in metachronous liver metastases were higher than those in primary tumors (TS, p=0.0084; ERCC1, p=0.037). However, there was no difference in the TS and ERCC1 mRNA levels between primary tumors and synchronous liver metastasis. The measurement of TS and ERCC1 mRNA levels in primary colorectal cancer can predict those in synchronous liver metastases, but not in metachronous ones.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020759

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.

Authors:  Kensuke Kumamoto; Koki Kuwabara; Yusuke Tajima; Kunihiko Amano; Satoshi Hatano; Tomonori Ohsawa; Norimichi Okada; Keiichiro Ishibashi; Norihiro Haga; Hideyuki Ishida
Journal:  Oncol Lett       Date:  2012-02-09       Impact factor: 2.967

Review 2.  Molecular testing to optimize therapeutic decision making in advanced colorectal cancer.

Authors:  Thomas J Semrad; Edward J Kim
Journal:  J Gastrointest Oncol       Date:  2016-04

3.  Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity?

Authors:  M López-Gómez; J Moreno-Rubio; I Suárez-García; P Cejas; R Madero; E Casado; A M Jiménez; M Sereno; C Gómez-Raposo; F Zambrana; M Merino; D Fernández-Luengas; J Feliu
Journal:  Clin Transl Oncol       Date:  2014-10-10       Impact factor: 3.405

Review 4.  The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review.

Authors:  A A P Slesser; P Georgiou; G Brown; S Mudan; R Goldin; P Tekkis
Journal:  Clin Exp Metastasis       Date:  2012-11-23       Impact factor: 5.150

5.  Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer.

Authors:  Luis Bujanda; Cristina Sarasqueta; Angel Cosme; Elizabeth Hijona; José M Enríquez-Navascués; Carlos Placer; Eloisa Villarreal; Marta Herreros-Villanueva; María D Giraldez; Meritxell Gironella; Francesc Balaguer; Antoni Castells
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.